- Home
- ICUI vs CRNX Comparison
ICUI vs CRNX Comparison
Compare ICUI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUI
- CRNX
- Stock Information
- Founded
- ICUI 1984
- CRNX 2008
- Country
- ICUI United States
- CRNX United States
- Employees
- ICUI N/A
- CRNX N/A
- Industry
- ICUI Medical/Dental Instruments
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- ICUI Health Care
- CRNX Health Care
- Exchange
- ICUI Nasdaq
- CRNX Nasdaq
- Market Cap
- ICUI 3.4B
- CRNX 2.8B
- IPO Year
- ICUI 1992
- CRNX 2018
- Fundamental
- Price
- ICUI $133.44
- CRNX $31.75
- Analyst Decision
- ICUI Strong Buy
- CRNX Strong Buy
- Analyst Count
- ICUI 5
- CRNX 8
- Target Price
- ICUI $196.75
- CRNX $74.86
- AVG Volume (30 Days)
- ICUI 215.9K
- CRNX 725.8K
- Earning Date
- ICUI 08-06-2025
- CRNX 08-07-2025
- Dividend Yield
- ICUI N/A
- CRNX N/A
- EPS Growth
- ICUI N/A
- CRNX N/A
- EPS
- ICUI N/A
- CRNX N/A
- Revenue
- ICUI $2,420,093,000.00
- CRNX $760,000.00
- Revenue This Year
- ICUI N/A
- CRNX $402.02
- Revenue Next Year
- ICUI N/A
- CRNX $771.03
- P/E Ratio
- ICUI N/A
- CRNX N/A
- Revenue Growth
- ICUI 7.22
- CRNX N/A
- 52 Week Low
- ICUI $117.92
- CRNX $24.10
- 52 Week High
- ICUI $196.26
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- ICUI 50.47
- CRNX 57.94
- Support Level
- ICUI $129.26
- CRNX $28.98
- Resistance Level
- ICUI $139.41
- CRNX $32.49
- Average True Range (ATR)
- ICUI 4.24
- CRNX 1.24
- MACD
- ICUI 0.53
- CRNX 0.30
- Stochastic Oscillator
- ICUI 59.68
- CRNX 90.54
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.